Adult T-cell leukemia–lymphoma (ATL) is a peripheral T-cell malignancy, closely associated with human T-cell lymphotropic virus type I infection. Clinically, ATL is classified into four subtypes: ...
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...
While rare, secondary cancers after CAR T-cell therapy have been reported, leading the FDA to mandate boxed warnings on all approved therapies. In a first, targeted therapy was used to treat a T-cell ...
Citius Oncology Inc. has commercially launched Lymphir, a treatment for Stage I–III cutaneous T-cell lymphoma, the Cranford-based firm announced Dec. 1. In August 2024, the U.S. Food and Drug ...
Mature nodal T-cell lymphoma is a type of rare and aggressive blood cancer. Limited data make it difficult to identify high-risk patients or tailor treatment strategies, so most patients receive ...
Immunotherapy uses the power of your immune system to fight your cancer. There are several types of immunotherapies. They include antibody therapies and CAR T-cell therapy. Immunotherapies are among ...
Initiating first-in-human Phase 1 trial in H1 of 2024 PHILADELPHIA, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) ...
Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a rare subtype of non-Hodgkin lymphoma that frequently presents with multiorgan involvement. We report a diagnostically challenging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results